Nurse Practitioner, Family · Philadelphia, PA
NPI
1083159248
Since 2016
Specialty
Nurse Practitioner, Family
Code 363LF0000X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
925 Chestnut St
Philadelphia, PA, 19107
Phone (856) 977-4423
Groups this clinician bills Medicare through
Medicare paid, 2024
$4,666
71 services
Medicare patients, 2024
39
Average age 72
Drug cost, 2024
$3.4M
534 prescriptions
Company payments, 2023
$700
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Kaitlin A Rancani was code 99215 (office e&m - established), 21 times for 15 patients. In total Kaitlin A Rancani billed 71 services in 8 codes, and Medicare paid $4,666.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-04-01.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99215 Office E&M - Established | Facility | 21 | 15 | $89.35 | $1,876 |
| 38222 Other Organ Systems | Facility | 14 | 13 | $50.89 | $713 |
By year: 2022 $2,256 for 42 services; 2023 $3,984 for 65 services; 2024 $4,666 for 71 services.
Medicare prescription drug claims, 2024
In 2024, the drug Kaitlin A Rancani prescribed most often to Medicare patients was Xospata (Gilteritinib Fumarate), with 41 prescriptions and refills. In total Kaitlin A Rancani wrote 534 Medicare prescriptions that cost $3.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Xospata Gilteritinib Fumarate | 41 | 41 | Under 11 | $1.0M |
| Valacyclovir Valacyclovir Hcl | 31 | 69 | 14 | $3,692 |
| Acyclovir Generic | 26 | 46 | Under 11 | $720 |
| Ondansetron Hcl Generic | 20 | 20 | 15 | $115 |
| Venclexta Venetoclax | 20 | 20 | Under 11 | $204K |
| Gabapentin Generic | 19 | 25 | Under 11 | $181 |
| Iclusig Ponatinib Hcl | 17 | 17 | Under 11 | $367K |
| Levofloxacin Generic | 17 | 21 | 11 | $408 |
| Prochlorperazine Maleate Generic | 15 | 15 | Under 11 | $292 |
| Bosulif Bosutinib | 15 | 15 | Under 11 | $241K |
| Imatinib Mesylate Generic | 15 | 15 | Under 11 | $4,158 |
| Tibsovo Ivosidenib | 14 | 14 | Under 11 | $451K |
| Promacta Eltrombopag Olamine | 14 | 14 | Under 11 | $421K |
| Voriconazole Generic | 13 | 17 | Under 11 | $2,106 |
| Fludrocortisone Acetate Generic | 11 | 11 | Under 11 | $133 |
Brand drugs: 186 claims; generic drugs: 348 claims; opioid claims: 11.
Money and other things of value reported by the companies
In 2023, drug and medical device companies paid Kaitlin A Rancani $700 ($700 in general payments such as food, travel and fees) from 1 company. The largest payer was CTI BioPharma Corp. with $700.
| Company | Payments | Amount |
|---|---|---|
| CTI BioPharma Corp. | 1 | $700 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.